![Daniel Vlock](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daniel Vlock
Directeur Général chez
ALOPEXX, INC.
Profil
Dr. Daniel R.
Vlock, MD, is a Chief Medical Officer at TransCode Therapeutics, Inc., a Chairman & Chief Executive Officer at Alopexx Enterprises LLC, a Chairman, President & Chief Executive Officer at Alopexx, Inc., a Chief Executive Officer at Alopexx Pharmaceuticals LLC, a Chairman at Valerion Therapeutics LLC and a President & Chief Executive Officer at Alopexx Vaccines LLC.
Dr. Vlock was previously employed as a Vice President-Clinical Research by ARIAD Pharmaceuticals, Inc., a Principal by Boehringer Ingelheim Corp., a Principal by Ethicon Endo-Surgery, Inc., a Principal by GPC Biotech, Inc., a Faculty Member by Harvard Medical School, a Principal by Pharmacia Corp., a Faculty Member by University of Pittsburgh School of Medicine, and a Faculty Member by Yale University.
He also served on the board at Kolltan Pharmaceuticals, Inc. He received his undergraduate degree from Cornell University and a doctorate degree from Baylor College of Medicine.
Postes actifs de Daniel Vlock
| Sociétés | Poste | Début |
|---|---|---|
| ALOPEXX, INC. | Directeur Général | 01/01/2021 |
| TRANSCODE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 28/03/2024 |
Valerion Therapeutics LLC
 Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Develops targeted therapies for orphan genetic diseases | Président | - |
Alopexx Vaccines LLC | Directeur Général | - |
Alopexx Enterprises LLC
 Alopexx Enterprises LLC BiotechnologyHealth Technology Engages in investing and managing health care companies | Directeur Général | 01/01/2006 |
Alopexx Pharmaceuticals LLC
 Alopexx Pharmaceuticals LLC Aerospace & DefenseElectronic Technology Part of Alopexx Enterprises LLC, Alopexx Pharmaceuticals LLC is a biotechnology company based in MA. Alopexx Pharmaceuticals LLC specializes in the development of immune therapeutics for microbial diseases. Founded in 2011 by Daniel R. Vlock, Alopexx focuses on creating broad-spectrum immune approaches to prevent and treat bacterial, fungal, and parasitic infections. The company's technology targets the surface polysaccharide, poly N-acetyl glucosamine (Pnag), which is present on over 75 distinct pathogens. Alopexx's product pipeline includes a fully human monoclonal antibody, F598, and a vaccine candidate, Av0328, both of which have shown promising results in clinical trials. The company aims to reduce the reliance on antibiotics by developing therapies that utilize the host's immune system, thereby preventing the development of antibiotic resistance. Daniel R. Vlock has been the CEO since incorporation. | Directeur Général | 01/10/2011 |
Anciens postes connus de Daniel Vlock
| Sociétés | Poste | Fin |
|---|---|---|
GPC Biotech, Inc.
 GPC Biotech, Inc. Drugstore ChainsRetail Trade Develops anticancer drugs | Corporate Officer/Principal | - |
| ARIAD PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Kolltan Pharmaceuticals, Inc.
 Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures monoclonal antibody drugs | Directeur/Membre du Conseil | - |
| ░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Daniel Vlock
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
26
Relations au 1er degré
17
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 17 |
|---|---|
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures monoclonal antibody drugs | Health Technology |
GPC Biotech, Inc.
GPC Biotech, Inc. Drugstore ChainsRetail Trade Develops anticancer drugs | Retail Trade |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Researches, manufactures and sells pharmaceuticals | Health Technology |
Ethicon Endo-Surgery, Inc.
 Ethicon Endo-Surgery, Inc. Medical SpecialtiesHealth Technology Manufactures surgical devices and equipments | Health Technology |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Baylor College of Medicine
 Baylor College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets health care products | Health Technology |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Valerion Therapeutics LLC
Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Develops targeted therapies for orphan genetic diseases | Health Technology |
Alopexx Pharmaceuticals LLC
Alopexx Pharmaceuticals LLC Aerospace & DefenseElectronic Technology Part of Alopexx Enterprises LLC, Alopexx Pharmaceuticals LLC is a biotechnology company based in MA. Alopexx Pharmaceuticals LLC specializes in the development of immune therapeutics for microbial diseases. Founded in 2011 by Daniel R. Vlock, Alopexx focuses on creating broad-spectrum immune approaches to prevent and treat bacterial, fungal, and parasitic infections. The company's technology targets the surface polysaccharide, poly N-acetyl glucosamine (Pnag), which is present on over 75 distinct pathogens. Alopexx's product pipeline includes a fully human monoclonal antibody, F598, and a vaccine candidate, Av0328, both of which have shown promising results in clinical trials. The company aims to reduce the reliance on antibiotics by developing therapies that utilize the host's immune system, thereby preventing the development of antibiotic resistance. Daniel R. Vlock has been the CEO since incorporation. | Electronic Technology |
University of Pittsburgh School of Medicine
 University of Pittsburgh School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alopexx Enterprises LLC
Alopexx Enterprises LLC BiotechnologyHealth Technology Engages in investing and managing health care companies | Health Technology |
TransCode Therapeutics, Inc.
 TransCode Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes diagnostics and therapeutics for the detection and treatment of cancer | Health Technology |
Alopexx Vaccines LLC | |
Alopexx, Inc.
 Alopexx, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company which develops novel and broad-spectrum immune-mediated therapeutics | Health Technology |
